Literature DB >> 23638319

RNA aptamers and their therapeutic and diagnostic applications.

Katherine Germer1, Marissa Leonard, Xiaoting Zhang.   

Abstract

RNA Aptamers refer to RNA oligonulceotides that are capable of binding to specific targets with high affinity and specificity. Through a process called Systematic Evolution of Ligands by EXponential enrichment (SELEX), a number of RNA aptamers have been identified against various targets including organic compounds, nucleotides, proteins and even whole cells and organisms. RNA aptamers have proven to be of high therapeutic and diagnostic value with recent FDA approval of the first aptamer drug and additional ones in the clinical pipelines. It has also been found to be a particularly useful tool for cell-type specific delivery of other RNA therapeutics like siRNA. All these establish RNA aptamers as one of the pivotal tools of the emerging RNA nanotechnology field in the fight against human diseases including cancer, viral infections and other diseases. This article summarizes the current advancement in the identification of RNA aptamers and also provides some examples of their therapeutic and diagnostic applications.

Entities:  

Keywords:  RNA aptamer; RNA nanotechnology; RNA therapy; SELEX; drug delivery

Year:  2013        PMID: 23638319      PMCID: PMC3627066     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  84 in total

Review 1.  Gene therapy progress and prospects: RNA aptamers.

Authors:  N S Que-Gewirth; B A Sullenger
Journal:  Gene Ther       Date:  2007-02       Impact factor: 5.250

2.  Calcium-dependent oligonucleotide antagonists specific for L-selectin.

Authors:  D O'Connell; A Koenig; S Jennings; B Hicke; H L Han; T Fitzwater; Y F Chang; N Varki; D Parma; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor.

Authors:  H Ulrich; J E Ippolito; O R Pagán; V A Eterović; R M Hann; H Shi; J T Lis; M E Eldefrawi; G P Hess
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

4.  RNA aptamers that specifically bind to the Ras-binding domain of Raf-1.

Authors:  M Kimoto; K Sakamoto; M Shirouzu; I Hirao; S Yokoyama
Journal:  FEBS Lett       Date:  1998-12-18       Impact factor: 4.124

Review 5.  Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.

Authors:  Eugene W M Ng; Anthony P Adamis
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

6.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

7.  Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.

Authors:  N Bardeesy; J Pelletier
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

8.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

9.  Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells.

Authors:  Hee Kyu Lee; Yong Seok Choi; Young Ae Park; Sunjoo Jeong
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

10.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

View more
  45 in total

Review 1.  microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Xiaofei Li; Wenjun Yang; Lianqing Lou; Yongxin Chen; Shuang Wu; Guoqiang Ding
Journal:  Dig Dis Sci       Date:  2014-01-04       Impact factor: 3.199

Review 2.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

Review 3.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

Review 4.  Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis.

Authors:  Guo-Xiao Liu; Hong-Qing Xi; Xiao-Yan Sun; Bo Wei
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

5.  Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers.

Authors:  Jared Damare; Stephanie Brandal; Yolanda M Fortenberry
Journal:  Nucleic Acid Ther       Date:  2014-06-12       Impact factor: 5.486

6.  Aptamer TY04 inhibits the growth of multiple myeloma cells via cell cycle arrest.

Authors:  Hongjuan Dai; Mao Ye; Mingyuan Peng; Weihua Zhou; Huarong Bai; Xiaojuan Xiao; Bianying Ma; Jiajie Zhou; Shijun Tang; Shan Yao; Ye Cao; Zhiqiang Qin; Jing Liu; Weihong Tan
Journal:  Tumour Biol       Date:  2014-05-03

7.  RNA-Redesign: a web server for fixed-backbone 3D design of RNA.

Authors:  Joseph D Yesselman; Rhiju Das
Journal:  Nucleic Acids Res       Date:  2015-05-11       Impact factor: 16.971

Review 8.  Synthetic immunosurveillance systems: nanodevices to monitor physiological events.

Authors:  Yvon L Woappi; Rahul Jangiti; Om V Singh
Journal:  Biosens Bioelectron       Date:  2014-05-10       Impact factor: 10.618

9.  MUC1 aptamer-based near-infrared fluorescence probes for tumor imaging.

Authors:  Haiyan Chen; Juan Zhao; Min Zhang; Haibo Yang; Yuxiang Ma; Yueqing Gu
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

10.  Preparation and Properties of Nanoparticles, tRNA-Bivalent Metal Cation (Me2+) Complexes, and Prospects of Their Practical Use.

Authors:  V N Danilevich; V V Sorokin; Ya P Moiseev; S V Sizova
Journal:  Dokl Biochem Biophys       Date:  2018-05-19       Impact factor: 0.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.